Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the issuance of a new patent for a companion diagnostic, to be used as a...
(PRWeb July 31, 2012)
Read the full story at http://www.prweb.com/releases/2012/7/prweb9749628.htm